Drugs that contain Brexpiprazole
1. List of Rexulti drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7888362 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(3 years from now) | |
| USRE48059 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Dec, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618109 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(3 years from now) | |
| US8349840 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(3 years from now) | |
| US9839637 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(3 years from now) | |
| US10307419 | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Oct, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Dec 27, 2024 |
Market Authorisation Date: 10 July, 2015
Treatment: Treatment of schizophrenia; Treatment of schizophrenia in adults and pediatric patients ages 13 years and older; Adjunctive treatment of major depressive disorder (mdd)
Dosage: TABLET;ORAL
How can I launch a generic of REXULTI before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic